BRANČÍKOVÁ, Dagmar, Zdeněk MECHL, Zdeněk ADAM, Eva JANDÁKOVÁ, Zdeněk PAVLOVSKÝ, Vlastimil VÁLEK and Tomáš ANDRAŠINA. Patient with inoperable pheochromocytoma. Current Oncology. Toronto: Multimed INC., 2015, vol. 22, No 3, p. "E216"-"E219", 4 pp. ISSN 1198-0052. Available from: https://dx.doi.org/10.3747/co.22.2324.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Patient with inoperable pheochromocytoma
Authors BRANČÍKOVÁ, Dagmar (203 Czech Republic, guarantor, belonging to the institution), Zdeněk MECHL (203 Czech Republic), Zdeněk ADAM (203 Czech Republic, belonging to the institution), Eva JANDÁKOVÁ (203 Czech Republic, belonging to the institution), Zdeněk PAVLOVSKÝ (203 Czech Republic, belonging to the institution), Vlastimil VÁLEK (203 Czech Republic, belonging to the institution) and Tomáš ANDRAŠINA (703 Slovakia, belonging to the institution).
Edition Current Oncology, Toronto, Multimed INC. 2015, 1198-0052.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Canada
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.829
RIV identification code RIV/00216224:14110/15:00083405
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3747/co.22.2324
UT WoS 000356976100010
Keywords in English Pheochromocytoma; chemoembolization; lanreotide
Tags EL OK
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 13/1/2016 14:16.
Abstract
Malignant pheochromocytoma is a tumour with a very low incidence that occurs sporadically or in the presence of multiple endocrine neoplasia. We present the case of a woman with a sporadic occurrence of pheochromocytoma diagnosed in the phase of multiple dissemination in the abdominal cavity and overexpressing adrenaline, noradrenaline, and dopamine. Local transarterial chemoembolization and systemic treatment with lanreotide resulted in a very good response, a decrease in the production of catecholamines for 12 months and a partial decrease for another 8 months, with stabilization of disease determined by imaging. Systemic treatment with tegafur resulted in disease stabilization lasting 50 months, after which the drug was discontinued because of adverse effects. Maintenance therapy with lanreotide continues, and no disease progression has been observed for 4 months. The treatment algorithm for such patients is multidisciplinary and must always take into account the current scope of the disease, intercurrence, and the general condition of the patient.
PrintDisplayed: 24/7/2024 00:32